{"product_id":"dubois-lupus-erythematosus-and-related-syndromes-hardback-9780323479271","title":"Dubois' Lupus Erythematosus and Related Syndromes (Hardback) 9780323479271","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eDubois' Lupus Erythematosus and Related Syndromes\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cp\u003eThe definitive text for more than 50 years … now updated for the needs of today’s clinician\u003c\/p\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eDaniel J. Wallace (Author), Bevra Hahn (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780323479271, Elsevier Health Sciences\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 18 October 2018\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e816 pages\u003cbr\u003e27.6 x 21.5 x 4.1 cm, 2.42 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eFor more than 50 years, \u003ci\u003eDubois’ Lupus Erythematosus and Related Syndromes\u003c\/i\u003e has been recognized internationally as \u003cb\u003ethe go-to clinical reference on lupus and other connective tissue diseases\u003c\/b\u003e. From basic scientific principles to practical points of clinical management, the updated 9th Edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a \u003cb\u003elogical, clearly written, user-friendly\u003c\/b\u003e manner. It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes.\u003c\/p\u003e\n\u003cul\u003e \u003cli\u003eProvides \u003cb\u003ecomplete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus\u003c\/b\u003e, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education.\u003c\/li\u003e \u003cli\u003eContains an up-to-date overview of \u003cb\u003esignificant advances in cellular, molecular, and genetic technologies\u003c\/b\u003e, including genetic advancements in identifying at-risk patients.\u003c\/li\u003e \u003cli\u003eOffers an \u003cb\u003eincreased focus on the clinical management of related disorders\u003c\/b\u003e such as Sjogren’s syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS).\u003c\/li\u003e \u003cli\u003ePresents the knowledge and expertise of \u003cb\u003emore international contributors\u003c\/b\u003e to provide \u003cb\u003enew global perspectives\u003c\/b\u003e on manifestations, diagnosis, and treatment.\u003c\/li\u003e \u003cli\u003eFeatures a \u003cb\u003evibrant, full-color format\u003c\/b\u003e, with graphs, algorithms, differential diagnosis comparisons, and \u003cb\u003emore schematic diagrams\u003c\/b\u003e throughout.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eExpert Consult™ eBook version included with purchase.\u003c\/b\u003e This \u003cb\u003eenhanced eBook experience\u003c\/b\u003e allows you to search all of the text, figures, and references from the book on a variety of devices.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface, vii\u003c\/p\u003e \u003cp\u003eList of Contributors, viii\u003c\/p\u003e \u003cp\u003eSECTION 1 What Is Lupus?\u003c\/p\u003e \u003cp\u003e1 History of Lupus, 1\u003c\/p\u003e \u003cp\u003e2 Definition and Classification of Lupus and Lupus-Related\u003c\/p\u003e \u003cp\u003eDisorders, 15\u003c\/p\u003e \u003cp\u003e3 The Epidemiology of Lupus, 23\u003c\/p\u003e \u003cp\u003eSECTION 2 Pathogenesis\u003c\/p\u003e \u003cp\u003e4 Overview of Lupus Pathogenesis, 44\u003c\/p\u003e \u003cp\u003e5 Genetics of Human SLE, 54\u003c\/p\u003e \u003cp\u003e6 Epigenetics of Lupus, 69\u003c\/p\u003e \u003cp\u003e7 The Environment and the Host, 86\u003c\/p\u003e \u003cp\u003e8 The Innate Immune System in SLE, 93\u003c\/p\u003e \u003cp\u003e9 B Cells and Generation of Antibodies, 101\u003c\/p\u003e \u003cp\u003e10 T Cells, 116\u003c\/p\u003e \u003cp\u003e11 Adaptive and Innate Immunoregulatory Cells, 125\u003c\/p\u003e \u003cp\u003e12 Cytokines in Lupus, 137\u003c\/p\u003e \u003cp\u003e13 Immunometabolism, 153\u003c\/p\u003e \u003cp\u003e14 Animal Models in Lupus, 164\u003c\/p\u003e \u003cp\u003eSECTION 3 Mechanisms of Tissue Injury\u003c\/p\u003e \u003cp\u003e15 Abnormalities in Immune Complex Clearance and\u003c\/p\u003e \u003cp\u003eApoptotic Cell Clearance, 216\u003c\/p\u003e \u003cp\u003e16 The Role of Complement in SLE, 224\u003c\/p\u003e \u003cp\u003e17 Apoptosis and Inflammatory Forms of Cell Death, 237\u003c\/p\u003e \u003cp\u003e18 Tissue Damage in Lupus: Free Radicals and Fibrosis, 248\u003c\/p\u003e \u003cp\u003e19 Pathogenesis of Fibrosis—The Lung as a Model, 261\u003c\/p\u003e \u003cp\u003e20 Pathogenesis of Lupus Nephritis, 269\u003c\/p\u003e \u003cp\u003e21 Pathogenesis of Accelerated Atherosclerosis and\u003c\/p\u003e \u003cp\u003eVascular Injury in Systemic Lupus Erythematosus, 294\u003c\/p\u003e \u003cp\u003e22 Pathogenesis of Cutaneous Lupus, 305\u003c\/p\u003e \u003cp\u003e23 Pathogenesis of Neuropsychiatric Lupus, 317\u003c\/p\u003e \u003cp\u003e24 Pathogenesis of Antiphospholipid Antibody\u003c\/p\u003e \u003cp\u003eSyndrome, 324\u003c\/p\u003e \u003cp\u003e25 Pathogenesis of Sjögren’s, 338\u003c\/p\u003e \u003cp\u003eSECTION 4 Autoantibodies\u003c\/p\u003e \u003cp\u003e26 Structure and Derivation of Autoantibodies, 340\u003c\/p\u003e \u003cp\u003e27 Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes, 355\u003c\/p\u003e \u003cp\u003e28 Antibodies Against ENA (Sm, RNP, SSA, SSB), 366\u003c\/p\u003e \u003cp\u003e29 Antibodies Against C1q, 372\u003c\/p\u003e \u003cp\u003e30 Antilipoprotein and Antiendothelial Cell\u003c\/p\u003e \u003cp\u003eAntibodies, 375\u003c\/p\u003e \u003cp\u003e31 Drug-Induced Lupus Erythematosus, 377\u003c\/p\u003e \u003cp\u003eSECTION 5 Clinical Aspects of Lupus\u003c\/p\u003e \u003cp\u003eErythematosus\u003c\/p\u003e \u003cp\u003e32 Overview and Clinical Presentation, 389\u003c\/p\u003e \u003cp\u003e33 Skin Disease in Cutaneous Lupus Erythematosus, 395\u003c\/p\u003e \u003cp\u003e34 The Musculoskeletal System and Bone\u003c\/p\u003e \u003cp\u003eMetabolism, 407\u003c\/p\u003e \u003cp\u003e35 Lupus and the Cardiopulmonary System, 418\u003c\/p\u003e \u003cp\u003e36 Lupus and the Nervous System: Clinical Aspects, Psychopathology, and Imaging, 434\u003c\/p\u003e \u003cp\u003e37 Gastrointestinal and Hepatic Systems, 457\u003c\/p\u003e \u003cp\u003e38 Hematologic and Lymphoid Abnormalities in SLE, 473\u003c\/p\u003e \u003cp\u003e39 Neonatal Lupus: Pathogenesis and Clinical\u003c\/p\u003e \u003cp\u003eApproaches, 486\u003c\/p\u003e \u003cp\u003e40 Pregnancy and Autoimmune Disease, Reproductive and\u003c\/p\u003e \u003cp\u003eHormonal Issues, 499\u003c\/p\u003e \u003cp\u003e41 Systemic Lupus Erythematosus in Childhood and\u003c\/p\u003e \u003cp\u003eAdolescence, 520\u003c\/p\u003e \u003cp\u003e42 Clinical Aspects of Antiphospholipid Syndrome, 532\u003c\/p\u003e \u003cp\u003e43 Lupus and Infections, 543\u003c\/p\u003e \u003cp\u003e44 Ocular, Aural, and Oral Manifestations of Lupus, 556\u003c\/p\u003e \u003cp\u003e45 Clinical Aspects of Sjögren’s, 566\u003c\/p\u003e \u003cp\u003eSECTION 6 Assessment of Lupus\u003c\/p\u003e \u003cp\u003e46 Clinical Application of Serologic Tests, Serum Protein\u003c\/p\u003e \u003cp\u003eAbnormalities, and Other Clinical Laboratory Tests in\u003c\/p\u003e \u003cp\u003eSystemic Lupus Erythematosus, 579\u003c\/p\u003e \u003cp\u003e47 Differential Diagnosis and Disease Associations, 598\u003c\/p\u003e \u003cp\u003e48 Incomplete Lupus, Undifferentiated Connective Tissue\u003c\/p\u003e \u003cp\u003eDisease, and Mixed Connective Tissue Disease, 606\u003c\/p\u003e \u003cp\u003e49 Clinical Markers, Metrics, Indices, and Clinical\u003c\/p\u003e \u003cp\u003eTrials, 614\u003c\/p\u003e \u003cp\u003e50 Lupus Biomarkers, 631\u003c\/p\u003e \u003cp\u003eSECTION 7 Management of Lupus\u003c\/p\u003e \u003cp\u003e51 Principles of Therapy, Local Measures, and NSAIDs, 640\u003c\/p\u003e \u003cp\u003e52 Antimalarial Medications, 650\u003c\/p\u003e \u003cp\u003e53 Systemic Glucocorticoid Therapy for SLE, 661\u003c\/p\u003e \u003cp\u003e54 Immunosuppressive Drug Therapy, 673\u003c\/p\u003e \u003cp\u003e55 Complementary and Alternative Medications, Specialized and Niche Therapies, 689\u003c\/p\u003e \u003cp\u003e56 Adjunctive Treatments and Preventive Measures, 702\u003c\/p\u003e \u003cp\u003e57 Targeted Therapies in SLE, 710\u003c\/p\u003e \u003cp\u003e58 Management of Cutaneous Lupus Erythematosus, 719\u003c\/p\u003e \u003cp\u003e59 Epidemiology and Management of Lupus Nephritis, 727\u003c\/p\u003e \u003cp\u003e60 Management of Sjögren’s, 745\u003c\/p\u003e \u003cp\u003eSECTION 8 Outcomes\u003c\/p\u003e \u003cp\u003e61 Socioeconomic and Disability Aspects, 759\u003c\/p\u003e \u003cp\u003e62 Prognosis and Mortality of SLE, 770\u003c\/p\u003e \u003cp\u003eIndex, 782\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Rheumatology [\u003ca title=\"See our other books on Rheumatology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Rheumatology%20%5BMJM%5D%22\"\u003eMJM\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Elsevier","offers":[{"title":"Default Title","offer_id":46648527552792,"sku":"9780323479271","price":120.89,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780323479271_fe160828-cacf-488c-9035-231d49f0ec7a.jpg?v=1694989840","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/dubois-lupus-erythematosus-and-related-syndromes-hardback-9780323479271","provider":"Freshly Printed Books","version":"1.0","type":"link"}